REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedPreclinical

Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting.

Levolger S, Wiemer E A C, van Vugt J L A, Huisman S A, van Vledder M G, van Damme-van Engel S, Ambagtsheer G, IJzermans J N M, de Bruin R W F
Scientific reports2019DOI: 10.1038/s41598-019-46178-9
SB431542GW788388LR3 IGF-I

Quality Score

4/10

Citations

0

Subjects

Non-Human

PeptideVault Analysis

Study Design

Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.

Our Assessment

Quality Assessment: 4/10 — This study contributes useful data but has methodological limitations that warrant caution. The findings are suggestive rather than definitive, and we'd recommend looking for corroborating evidence before drawing strong conclusions.

Findings in Context

The evidence for SB431542, GW788388, LR3 IGF-I here is mixed or preliminary. This is an honest result — not every study produces a clear winner, and acknowledging uncertainty is itself valuable for the field.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Early-stage evidence for SB431542, GW788388, LR3 IGF-I. Interesting mechanistic insights, but we'll need human data before drawing practical conclusions.

Key Findings

The study found that GW788388 was effective in preventing cancer cachexia and downregulating Atrogin-1 expression, while LR3 IGF-I limited muscle mass loss but accelerated tumor growth.

Limitations

The study is preclinical with no human subjects involved, limiting direct clinical applicability. The use of mouse models may not fully translate to human conditions.

Citation

Levolger S, Wiemer E A C, van Vugt J L A et al.. (2019). Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting.. Scientific reports. https://doi.org/10.1038/s41598-019-46178-9

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.